文献类型：期刊文献

中文题名：咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病的疗效评价

英文题名：Evaluation of Clinical Effects of KeChuanNing Capsules in Treating Chronic Obstructive Pulmonary Disease at Stable Stage

作者：张旭辉[1];杨虹[1]

第一作者：张旭辉

机构：[1]甘肃中医药大学附属医院,甘肃兰州730020

第一机构：甘肃中医药大学第二附属医院

年份：2016

卷号：29

期号：3

起止页码：1

中文期刊名：西部中医药

外文期刊名：Western Journal of Traditional Chinese Medicine

收录：CSTPCD

基金：甘肃省青年基金项目(编号1011FKCA095)

语种：中文

中文关键词：慢性阻塞性肺疾病;疗效评价;随机对照试验;咳喘宁胶囊

外文关键词：chronic obstructive pulmonary disease;evaluation on clinical effects;randomized controlled trial;Ke Chuan Ning capsules

摘要：目的:观察咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法:将COPD稳定期患者100例按照随机数字表法随机分为治疗组和对照组各50例。2组患者均口服茶碱缓释片0.1 g/次,2次/d,治疗组患者在此基础上口服咳喘宁胶囊,4粒/次,3次/d;对照组患者在此基础上口服等剂量安慰剂胶囊,4粒/次,3次/d,2组疗程均为3个月。观察临床疗效及BODE指数评分、体质指数(BMI)、肺功能、呼吸困难程度、6分钟步行距离测试(6MWD)、生活质量、安全性。结果:2组患者临床疗效比较治疗组优于对照组,ITT:Z=-1.96,P=0.041;PP:Z=-2.01,P=0.039;治疗组治疗后BODE指数和CAT量表评分明显下降(P<0.05)。结论:咳喘宁胶囊能有效降低稳定期COPD患者BODE指数及CAT评分,提高患者生活质量和临床疗效,且未发现明显毒副作用。
Objective: To observe clinical effects of KeChuanNing capsules in treating chronic obstructive pulmonary disease(COPD) at stable stage. Methods: One hundred patients were divided into the treatment group and the control group according to random number table, 50 cases each group. Both groups took theophylline sustained-release tablets, 0.1g each time, twice per day, the treatment group took KeChuan Ning capsules, four pills each time, three times per day; the control group were administered with placebo capsules in equivalent dose, four pills each time, three times per day, both groups were treated for three months. Clinical effects, BODE index scales, body mass index(BMI), pulmonary function, dyspnea degree, six minutes walking test(6MWD), quality of life and the safety were observed. Results: The treatment group was superior to the control group in the comparison of clinical effects between both groups ITT: Z=-1.96, P=0.041; PP: Z=-2.01, P=0.039; BODE index and CAT scales of the treatment group lowered significantly(P <0.05). Conclusion: KeChuan Ning capsules could effectively decrease BODE index and CAT scales of COPD patients, and improve quality of life and curative effects of the patients, and no obvious toxicity and adverse reaction is found.